

| Drug                                    | Schedule |
|---|----------|
| Gamma hydroxybutyric acid (2010) .....  | I        |
| Ibogaine (7260) .....                   | I        |
| Lysergic acid diethylamide (7315) ..... | I        |
| Tetrahydrocannabinols (7370) .....      | I        |
| Dimethyltryptamine (7435) .....         | I        |
| Dihydromorphine (9145) .....            | I        |
| Amphetamine (1100) .....                | II       |
| Methamphetamine (1105) .....            | II       |
| Amobarbital (2125) .....                | II       |
| Phencyclidine (7471) .....              | II       |
| Phenylacetone (8501) .....              | II       |
| Cocaine (9041) .....                    | II       |
| Codeine (9050) .....                    | II       |
| Dihydrocodeine (9120) .....             | II       |
| Oxycodone (9143) .....                  | II       |
| Hydromorphone (9150) .....              | II       |
| Ecgonine (9180) .....                   | II       |
| Hydrocodone (9193) .....                | II       |
| Meperidine (9230) .....                 | II       |
| Metazocine (9240) .....                 | II       |
| Morphine (9300) .....                   | II       |
| Thebaine (9333) .....                   | II       |
| Oxymorphone (9652) .....                | II       |
| Fentanyl (9801) .....                   | II       |

The company plans to manufacture small quantities of the listed controlled substances as radiolabeled compounds for biochemical research.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 23, 2006.

Dated: August 15, 2006.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. E6-13840 Filed 8-21-06; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Importer of Controlled Substances; Notice of Application

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled

substance in Schedule I or II and prior to issuing a registration under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on March 31, 2006, Applied Science Labs, Division of Alltech Associates Inc., 2701 Carolean Industrial Drive, State College, Pennsylvania 16801, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in Schedule I and II:

| Drug                    | Schedule |
|-------------------------|----------|
| Heroin (9200) .....     | I        |
| Cocaine (9041) .....    | II       |
| Codeine (9050) .....    | II       |
| Meperidine (9230) ..... | II       |
| Methadone (9250) .....  | II       |
| Morphine (9300) .....   | II       |

The company plans to import these controlled substances for the manufacture of reference standards.

Any manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47.

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than September 21, 2006.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substances in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied.

Dated: August 15, 2006.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. E6-13843 Filed 8-21-06; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Manufacturer of Controlled Substances; Notice of Application

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 6, 2006, Cambrex North Brunswick, Inc., Technology Centre of New Jersey, 661 Highway One, North Brunswick, NJ 08902, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedule I and II:

| Drug                                       | Schedule |
|--|----------|
| N-Ethylamphetamine (1475) .....            | I        |
| Tetrahydrocannabinols (7370) .....         | I        |
| 2,5-Dimethoxyamphetamine (7396) .....      | I        |
| 3,4-Methylenedioxyamphetamine (7400) ..... | I        |
| 4-Methoxyamphetamine (7411) .....          | I        |
| Amphetamine (1100) .....                   | II       |
| Methamphetamine (1105) .....               | II       |
| Methylphenidate (1724) .....               | II       |
| Pentobarbital (2270) .....                 | II       |
| Phenylacetone (8501) .....                 | II       |
| Hydromorphone (9150) .....                 | II       |
| Hydrocodone (9193) .....                   | II       |
| Methadone (9250) .....                     | II       |
| Methadone Intermediate (9254) .....        | II       |
| Morphine (9300) .....                      | II       |
| Sufentanil (9740) .....                    | II       |
| Fentanyl (9801) .....                      | II       |

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).

Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL;